Abstract | PURPOSE: METHODS AND MATERIALS: RESULTS: A total of 200 patients were treated with carboplatin-5FU and 53 patients with cisplatin. Median potential follow-up was 43 months. The 3-year overall survival rates for carboplatin-5FU and cisplatin respectively were 79.1% and 74.9% (p = 0.628), the 3-year disease-free survival rates were 76.0% and 71.3% (p = 0.799), and the 3-year locoregional control rates were 88.4% and 94.2% (p = 0.244). CONCLUSIONS: We could not demonstrate differences between these two regimens, which both proved efficacious. Polychemotherapy and monochemotherapy therefore seem comparable in this retrospective analysis.
|
Authors | Maroie Barkati, Bernard Fortin, Denis Soulières, Sébastien Clavel, Phillipe Després, Danielle Charpentier, Jean-Claude Tabet, Louis Guertin, Marie-Jo Olivier, Geneviève Coulombe, David Donath, Phuc Felix Nguyen-Tan |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 76
Issue 2
Pg. 410-6
(Feb 01 2010)
ISSN: 1879-355X [Electronic] United States |
PMID | 19427745
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright 2010 Elsevier Inc. All rights reserved. |
Chemical References |
- Carboplatin
- Cisplatin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Squamous Cell
(drug therapy, mortality, radiotherapy)
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
(methods)
- Disease-Free Survival
- Female
- Fluorouracil
(administration & dosage)
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Oropharyngeal Neoplasms
(drug therapy, mortality, radiotherapy)
- Radiotherapy Dosage
- Retrospective Studies
- Survival Rate
- Treatment Outcome
|